ReviewHistology and histopathology2026
Treatment strategies for locally advanced and metastatic urothelial carcinoma based on molecular profiles: A Review.
Review in Histology and histopathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Timing-dependent skin toxicity phenotypes during enfortumab vedotin plus pembrolizumab therapy for advanced urothelial carcinoma.International journal of clinical oncology · 2026Article
- A Case of Upper Tract Urothelial Carcinoma With Neuroendocrine Differentiation Successfully Treated With Enfortumab Vedotin and Pembrolizumab.IJU case reports · 2026Article
- Oncolytic adenoviruses in bladder and kidney cancers: emerging strategies and next frontiers.Frontiers in microbiology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Urothelial carcinoma (UC), which includes bladder carcinoma (accounting for 90-95% of cases) and upper urinary tract carcinoma (comprising 5-10%), is one of the most prevalent malignancies worldwide. For several decades, platinum-based chemotherapy has been the primary treatment modality for this disease. However, recent advancements have significantly transformed the therapeutic landscape for patients with UC. This transformation has been facilitated by the introduction of various treatment options, including immune checkpoint inhibitors targeting PD-L1 or PD-1, antibody-drug conjugates that target nectin-4 or trophoblast cell surface antigen 2 expressed on cancer cells, and fibroblast growth factor receptor (FGFR) inhibitors specifically indicated for Patients with UC with FGFR3 mutations. Although these novel therapies have demonstrated marked survival benefits for patients with locally advanced or metastatic UC, their efficacy can vary depending on the specific molecular profile present on cancer cells. In this review, we summarize the molecular classifications of UC and the corresponding treatment landscape associated with these classifications.
Indexed as
Identifiers
40762043What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.